Antitrust Antitrust

Zoetis sees Virbac withdraw EU appeal of Librela approval

By Andrew Boyce
  • 02 Sep 2022 16:08
  • 02 Sep 2022 16:08
French animal-health company Virbac has withdrawn its case at the EU courts against the European Commission’s approval for Zoetis’s Librela, an innovative osteoarthritis medicine for dogs.

Virbac alleged in the appeal that Zoetis was abusing its market power. The French company started the litigation in March 2021, seven months before the

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Andrew Boyce


Andrew is a reporter covering merger reviews and competition policy for MLex in Brussels. He joined MLex in 2015 and holds a degree and a master’s degree in history from the University of Liverpool.

Discover MLex

Stay on top of global regulatory developments


Latest News